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Diabetes is associated with impairment of angiogenesis such as reduction of myocardial capillary formation. Our previous studies
demonstratethatdisruptionofAngiopoietin-1(Ang-1)/Tie-2signalingpathwaycontributestothediabetes-associatedimpairment
of angiogenesis. Protein tyrosine phosphatase (PTP) has a critical role in the regulation of insulin signal by inhibition of tyrosine
kinase phosphorylation. In present study, we examined the role of protein tyrosine phosphatase-1 (SHP-1) in diabetes-associated
impairment of Ang-1/Tie-2 angiogenic signaling and angiogenesis. SHP-1 expression was signiﬁcantly increased in diabetic db/db
mouse hearts. Furthermore, SHP-1 bond to Tie-2 receptor and stimulation with Ang-1 led to SHP-1 dissociation from Tie-2 in
mouse heart microvascular endothelial cell (MHMEC). Exposure of MHMEC to high glucose (HG, 30mmol/L) increased SHP-
1/Tie-2 association accompanied by a signiﬁcant reduction of Tie-2 phosphorylation. Exposure of MHMEC to HG also blunted
Ang-1-mediated SHP-1/Tie-2 dissociation. Knockdown of SHP-1 signiﬁcantly attenuated HG-induced caspase-3 activation and
apoptosis in MHMEC. Treatment with PTP inhibitors restored Ang-1-induced Akt/eNOS phosphorylation and angiogenesis. Our
dataimplicateacriticalroleofSHP-1indiabetes-associatedvascularcomplications,andthatupregulationofAng-1/Tie-2signaling
by targeting SHP-1 should be considered as a new therapeutic strategy for the treatment of diabetes-associated impairment of
angiogenesis.
1.Introduction
Angiogenesis is mainly regulated by the vascular endothe-
lial growth factor (VEGF)/VEGF receptor (VEGFR) and
the angiopoietins/Tie-2 system. Receptor tyrosine kinases
(RTKs) represent a major class of cell-surface molecules
that regulate angiogenesis. VEGFR and the Tie-2 receptor
are the principal RTK families and play critical roles in the
regulationofangiogenesis[1].Impairedangiogenesisleading
to microvascular insuﬃciency represents a major cause of
end-stage organ failure among diabetics. The underlying
molecular mechanisms, however, are poorly understood
[2, 3]. Myocardial angiogenesis is signiﬁcantly impaired in
patients with diabetes mellitus which may contribute to the
high mortality after myocardial infarction [4, 5]. So far, few
studies have focused on the identiﬁcation of factors that
aﬀect myocardial angiogenesis in the setting of diabetes. A
previous study showed that VEGF-induced migration and
VEGFR-mediatedsignaltransductionwereseverelyimpaired
in the monocytes of diabetic patients [6, 7]. Further, VEGFR
expression was signiﬁcantly reduced in the heart of diabetic
patients compared with nondiabetic individuals. This was
accompanied by an impairment of VEGFR phosphorylation,
suggesting that decreased VEGF expression and defective
VEGFsignalingmayplayakeyroleinthediabetes-associated
impairment of angiogenesis [8]. Our previous studies have
found that defective RTK signaling transduction is not
only limited to VEGF/VEGFR, but is also associated with2 Experimental Diabetes Research
the disruption of Ang-1/Tie-2 angiogenic signaling and
angiogenesisunderhyperglycemicconditionsandindiabetes
[9–11].
Protein tyrosine phosphatase (PTP) has been shown to
negatively regulate insulin signaling by dephosphorylation
of insulin receptor tyrosine kinase [12, 13]. PTP also
has a critical role in the regulation of growth factors
signal transduction by de-phosphorylation of RTK. PTP
inhibition has been shown to promote collateral growth
and enhance VEGF-induced angiogenesis in a rat model of
hindlimbischemia[14,15].Thecytoplasmicproteintyrosine
phosphatase-1(SHP-1)expressesprimarily inhematopoietic
lineages and endothelial cells [16–19] and negatively regu-
l a t e sg r o w t hf a c t o rr e c e p t o r sp h o s p h o r y l a t i o n[ 17, 18, 20,
21]. SHP-1 expression is upregulated as a result of abnormal
inﬂammatory responses in diabetes patients [22]. A previous
study revealed that Tie-2 receptor was the substrates for
tyrosine phosphatase-2 (SHP-2) [23]. To date, little is known
of the functional role of SHP-1 on the Ang-1/Tie-2 signaling
and impairment of angiogenesis in diabetes.
In our present study, we hypothesize that hyperglycemia
and diabetes impair Ang-1/Tie-2 signaling and angiogenesis
by a mechanism involving upregulation of SHP-1 expression
andSHP-1/Tie-2interaction.Ourdatasuggestthatincreased
SHP-1 has a crucial role in the diabetes-associated impair-
ment of angiogenesis by interfering with the Ang-1/Tie-2
angiogenic signaling.
2.MaterialsandMethods
2.1.MouseHeartMicrovascularEndothelialCells(MHMECs).
MHMECs was isolated from C57BL/6J mouse hearts and
cultured as previously described [24–26]. Primary cultures
of MHMEC, between passages 4 and 10, were used in all
experiments.
2.2. Endothelial Cell Apoptosis and Caspase-3 Activity. To
induce apoptosis, MHMEC were exposed to serum-free
medium for 72 hours under high glucose (HG, 30mmol/L)
or normal glucose (NG, 5mmol/L) conditions. Endothelial
cell apoptosis was measured by counting TUNEL positive
cells per 100 endothelial cells following the manufacturer’s
instructions (Promega, WI). Caspase-3 activity was mea-
sured using the caspase-3 kit (Sigma, MO).
2.3. Immunoprecipitation of Tie-2 and Blotting with SHP-
1 or Phospho-Tyrosine. MHMEC lysates were immuno-
precipitated with anti-mouseTie-2 antibody followed by
incubation with a 1:1 protein A: protein G-sepharose
slurry. The immunoprecipitates were then subjected to SDS-
PAGE gels and transferred to nitrocellulose membranes.
The membranes were immunoblotting anti-SHP-1 (1:1000,
Santa Cruz, CA) or anti-phospho-tyrosine (4G10, 1:1000
Upstate Biotech, NY). The membranes were washed and
incubated with a secondary antibody coupled to horseradish
peroxidase.
2.4. SHP-1, Tie-2, Akt, and eNOS Expression. Fifty micro-
grams of total protein of myocardial tissue or MHMEC
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Figure 1: Expression of SHP-1 in the control C57BL/6J and db/db
mouse hearts. Western blot showing SHP-1 expression in control
C57BL/6J and diabetic db/db mouse hearts. Densitometric data
shows that SHP-1 protein expression was signiﬁcantly increased in
diabetic db/db mouse hearts in comparison with control C57BL/6J
mice (n = 3-4 mice, ∗P<0.05).
lysates were separated using SDS-gel electrophoresis. The
membranes were immunoblotted with SHP-1 (1:1000),
eNOS and Tie-2 (1:1000, Cell Signaling Technology, MA)
antibodies. For eNOS and Akt phosphorylation, the mem-
branes were immunoblotted with rabbit anti-phospho-Akt
and anti-phospho-eNOS (1:1000, Cell Signaling, MA). β-
Actin was used as a loading control (1:1000, Cell Signaling
Technology, MA) on the same nitrocellulose blots after
stripping. The membranes were washed and incubated with
a secondary antibody coupled to horseradish peroxidase,
and densitometric analysis was carried out using image
acquisition and analysis software (TINA 2.0).
2.5. SHP-1 siRNA Transfection. MHMEC (approx. 80%
conﬂuent) was treated with SHP-1 siRNA (mouse, Santa
Cruz, CA) for 24 hours to inhibition of SHP-1 expression
according to the manufacturer’s instructions. Knockdown
of SHP-1 was conﬁrmed by Western blot analysis of SHP-1
protein expression (data not shown).
2.6. Measurement of MHMEC Survival by MTT Assay.
Cell survival was assayed using the MTT assay kit (Roche
Diagnostic Corp., Indianapolis, IN).
2.7. Systemic Delivery of a PTP Inhibitor in Diabetic db/db
Mice. The C57BL/6J mice and db/db mice were purchased
from Jackson Laboratory (Bar Harbor, Maine). Sixteen male
db/db mice at 12 weeks of age were divided into two groups:
[1] the PTP inhibitor treatment group: db/db mice (n = 8)Experimental Diabetes Research 3
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Figure 2: Immunoprecipitation and Western blot analysis showing that SHP-1 associates with Tie-2 receptor and high glucose alters the
SHP-1/Tie-2 association in MHMEC. (a) SHP-1 binds to the Tie-2 receptor under normal glucose (NG) conditions; exposure of MHMEC
to high glucose (HG) leads to a signiﬁcant increase in the SHP-1/Tie-2 association (n = 4 cell lines, ∗P<0.05). (b) Exposure of MHMEC
to high glucose (HG) conditions results in a signiﬁcant reduction of Tie-2 phosphorylation (n = 3 cell lines, ∗P<0.05). (c) Under normal
glucose (NG) conditions, stimulation of MHMEC with Ang-1 (250ng/mL) for 15 minutes leads to a dissociation of SHP-1 from Tie-2.
Under HG conditions, Ang-1 failed to induce SHP-1/Tie-2 dissociation. These results represent three diﬀerent cell lines and experiments.
received oral bioavailable organovanadium compound, bis-
(maltolato)oxovanadium (IV) (BMOV, 0.2g/L) in their
drinking water for 2 weeks; [2] the db/db control group
received drinking water alone for 2 weeks. All procedures
were in compliance with the Institute for Laboratory Ani-
mal Research Guide for the Care and Use of Laboratory
Animals and were approved by the University of Missis-
sippi Medical Center Institutional Animal Care and Use
Committee.
2.8. In Vivo Myocardial Capillary Density Analysis. The
experimental mouse hearts were harvested and immediately
ﬂashfrozen. Tissuesections wereincubated with ﬂuorescein-
labeled antibodies against Griﬀonia Bandeiraea Simplicifolia
Isolectin B4 (IB4, 1:200, Sigma Co) to label the endothelial
cells, and myocardial capillary density was measured using
image analysis software (Image J, NIH). The number of
capillaries (IB4) was counted and expressed as capillary
density per mm2 [9–11].
2.9. Ex Vivo Angiogenesis Assay. Mouse aortae were isolated
and collected from C57BL/6J and db/db mice, placed in the
middle of organ culture dishes and overlaid with 300μLo f
ECM gel (Sigma Co, MO). After solidiﬁcation, the ECM
gel was covered with 10% FBS EGM in the presence or
absence of recombinant human Ang-1 (250ng/mL). Vessel
outgrowth at day 5 was examined using a Nikon TE-300
microscope. The area of vessel outgrowth was quantiﬁed
usingimageacquisitionandanalysissoftware(ImageJ,NIH)
[9, 11, 25, 26].4 Experimental Diabetes Research
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Figure 3: Knockdown of SHP-1 by siRNA blunts HG-induced cell apoptosis in MHMEC. (a) Caspase-3 ELISA analysis showing that
transfection of MHMEC with SHP-1 siRNA signiﬁcantly attenuated caspase-3 activation under NG or HG conditions (n = 3 cell lines,
∗P<0.05). (b) TUNEL staining showing that MHMEC transfected with SHP-1 siRNA signiﬁcantly inhibited high glucose-induced
endothelial cell apoptosis (n = 3 cell lines, ∗P<0.05).
2.10. Statistical Analysis. All results were expressed as mean
± SD. Statistical analysis was performed using unpaired
student t-test. A P value < 0.05 denoted signiﬁcance.
3. Results
3.1. SHP-1 Expression Is Upregulated in the Diabetic db/db
Mouse Hearts. Western blot analysis showed that SHP-
1 protein was expressed both in C57BL/6J mouse and
diabetic db/db mouse hearts. Intriguingly, the expression
of SHP-1 protein was signiﬁcantly increased in db/db
mouseheartsincomparisontoC57BL/6Jcontrols(Figure 1).
The SHP-2 protein expression was unchanged in db/db
mouse hearts in comparison to C57BL/6J controls (data not
shown).
3.2. HG Increases SHP-1/Tie-2 Association and Decreases Tie-
2TyrosinePhosphorylationinMHMEC. Toexaminewhether
SHP-1 binds to Tie-2, MHMEC lysates were immuno-
precipitated with Tie-2 antibody and blotted with SHP-1
antibody. As shown in Figure 2(a), SHP-1 bond to Tie-2 and
formedaTie-2/SHP-1complex.ExposureofMHMECtoHG
(30mmol/L)resultedinasigniﬁcantincreaseinSHP-1/Tie-2
association. This was accompanied by a signiﬁcant decrease
in Tie-2 tyrosine phosphorylation (Figure 2(b)).
3.3. Ang-1 Induces SHP-1 Dissociation from Tie-2 and This
Eﬀect Is Ameliorated by HG in MHMEC. To determine
whether SHP-1 was involved in Ang-1-mediated Tie-2 acti-
vation, the eﬀect of Ang-1 on Tie-2/SHP-1 association was
examined. As shown in Figure 2(c), stimulation of MHMEC
with Ang-1 (250ng/mL) resulted in a dissociation of SHP-1
from Tie-2 receptor. Ang-1 failed to cause SHP-1dissociation
from Tie-2 under HG conditions (Figure 2(c)).
3.4. SHP-1 siRNA Attenuates HG-Induced Caspase-3 Activa-
tion and Apoptosis in MHMEC. Next, the functional role
of SHP-1 in high glucose-induced endothelial dysfunction
was investigated. Treatment of MHMEC with SHP-1 siRNA
signiﬁcantlysuppressedcaspase-3activityundernormalglu-
cose (NG) and HG conditions (Figure 3(a)). Further, treat-
ment of MHMEC with SHP-1 siRNA signiﬁcantly blunted
HG-induced endothelial cell apoptosis (Figure 3(b)).
3.5. Inhibition of PTP Promotes Ang-1-Induced Angiogenic
Signaling under HG Conditions. To further investigate the
role of PTP in the Ang-1/Tie-2 signaling, the PTP inhibitor
on Ang-1-induced Akt/eNOS phosphorylation was exam-
ined in MHMEC under HG conditions. MHMEC was
pretreated with PTP inhibitor sodium orthovanadate (OV,
5μM) for 30 minutes, followed by Ang-1 (250ng/mL)
treatment for 15 minutes. Exposure of MHMEC to OV
signiﬁcantly enhanced Ang-1-induced Akt and eNOS phos-
phorylationunderHGconditions.PretreatmentofMHMEC
with OV alone had no signiﬁcant eﬀect on Akt and eNOS
phosphorylation under HG conditions (Figures 4(b) and
4(b)).Experimental Diabetes Research 5
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Figure 4: Inhibition of PTP enhances Ang-1-induced Akt and eNOS phosphorylation under HG conditions. (a) Western blot showing that
pretreatment of MHMEC with the PTP inhibitor orthovanadate (OV, 5μM) for 30 minutes leads to an increase in Akt phosphorylation in
response to Ang-1 (250ng/mL) stimulation under high glucose conditions (n = 3, ∗P<0.05). (b) Western blot showing that pretreatment
of MHMEC with the PTP inhibitor OV for 30 minutes results in a signiﬁcant increase in Ang-1-induced eNOS phosphorylation under high
glucose conditions (n = 3, ∗P<0.05).
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Figure 5: Inhibition of PTP promotes Ang-1-induced suppression of caspase-3 activation and increases cell survival under HG conditions.
(a) Caspase-3 activity assay showing that exposure of MHMEC to Ang-1 signiﬁcantly attenuates HG-induced caspase-3 activation;
pretreatment of MHMEC with OV before the Ang-1 treatment further enhances the eﬀect of Ang-1 on caspase-3 activity under HG
conditions (n = 3–5 cell lines, #P<0.05 versus NG, ∗P<0.05 versus HG). (b) MTT assay for the cell survival showing that pretreatment
with Ang-1 increases endothelial cell survival; pretreatment with OV before the Ang-1 treatment further enhances the eﬀect of Ang-1 on
endothelial cell survival under HG conditions (n = 3–5 cell lines, #P<0.05 versus NG, ∗P<0.05 versus HG).
3.6. Inhibition of PTP Enhances Ang-1-Mediated Cell Sur-
vival in MHMEC. Treatment of MHMEC with Ang-1
(250ng/mL) signiﬁcantly attenuated caspase-3 activity. The
inhibitory eﬀect of Ang-1 on caspase-3 activity was further
enhanced in the presence of OV (Figure 5(a)). Ang-1
has a critical role in the regulation of endothelial cell
survival. Treatment of MHMEC with Ang-1 (250ng/mL)
also increased cell survival under HG conditions. Similarly,6 Experimental Diabetes Research
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Figure 6: Treatment with PTP inhibitor restores the angiogenic response to Ang-1 in diabetic db/db mouse. (a) Representative images
of Ang-1-induced aortic explants sprouting in C57BL/6J and diabetic db/db mice. Stimulation of C57BL/6J mouse aortic explants with
Ang-1 (250ng/mL) leads to robust vessel outgrowth. Ang-1-induced vessel outgrowth was blunted in the db/db mouse aortic explants. (b)
Representative images of Ang-1-induced vessel outgrowth in the db/db mouse aortic explants in the presence and absence of PTP inhibitor
OV. (c) Quantitative areas of vessel outgrowth in db/db mouse aortic explants showing Ang-1-induced vessel outgrowth were signiﬁcantly
increased in the presence of PTP inhibitor OV (n = 4–8 mice, ∗P<0.05).Experimental Diabetes Research 7
β-actin
db/db mice
db/db
db/db mice + BMOV
S
H
P
-
1
/
β
-
a
c
t
i
n
 
r
a
t
i
o
db/db + BMOV
SHP-1
1.5
1
0.5
0
∗
(a)
β-actin
db/db mice
db/db
db/db mice + BMOV
db/db + BMOV
eNOS
1.5
1
2
0.5
0
∗
e
N
O
S
/
β
-
a
c
t
i
n
 
r
a
t
i
o
(b)
db/db
WT
0
200
400
600
800
1000
1200
1400
BMOV
∗
∗
+
++
+
−
−−
− −
M
y
o
c
a
r
d
i
a
l
 
c
a
p
i
l
l
a
r
y
 
d
e
n
s
i
t
y
 
(
m
m
2
)
(c)
db/db db/db/BMOV
(d)
Figure 7: Systemic treatment with the PTP inhibitor attenuates SHP-1 expression and increases eNOS and myocardial capillary density in
db/db mice. (a) Western blot analysis showing that treatment with BMOV for 2 weeks leads to a signiﬁcant suppression of SHP-1 expression
in the db/db mice compared to db/db control without BMOV (n = 3m i c e ,∗P<0.05). (b) Western blot analysis showing that treatment
with BMOV for 2 weeks results in a signiﬁcant increase in eNOS expression in the db/db mice compared to db/db control (n = 3-4 mice,
∗P<0.05). (c) Myocardial capillary density was signiﬁcantly increased in the BMOV-treated db/db mice compared to db/db control with
BMOV (n = 8, ∗P<0.05). (d) Quantitation of areas of vessel outgrowth showing Ang-1-induced vessel explants sprouting is signiﬁcantly
improved in the BMOV-treated db/db mice compared to db/db control group (n = 4–8 mice, ∗P<0.05).8 Experimental Diabetes Research
SHP-1
eNOS Akt
T
i
e
-
2
 
(a)
p
p
p
SHP
Ang-1
-1
eNOS
Akt
T
i
e
-
2
 
(b)
SHP-1 eNOS
Akt
T
i
e
-
2
 
Ang-1
(c)
Figure 8: Illustrating our working hypothesis for the SHP-1-induced disruption of Ang-1/Tie-2 signaling under HG conditions and in
diabetes. (a) In a resting state, SHP-1 maintains Tie-2 inactivation. (b) Stimulation with Ang-1 causes a dissociation of SHP-1 and Tie-2,
thus leading to Tie-2 tyrosine phosphorylation, and its downstream signaling Akt and eNOS activation. (c) Stimulation with Ang-1 fails to
lead to the dissociation of SHP-1 and Tie-2, thus resulting in a disruption of Ang-1/Tie-2 signaling under hyperglycemic conditions and in
diabetes. NG: normal glucose; HG: high glucose; SHP-1: protein tyrosine phosphatase-1.
Ang-1-induced cell survival was greatly enhanced in the
presenceofOVunderHGconditions.Surprisingly,OValone
had little eﬀect on cell survival (Figure 5(b)).
3.7. Inhibition of PTP Augments Ang-1-Induced Vessel Out-
growth in db/db Mouse. As shown in Figure 6(a),e x p o s u r e
of C57BL/6J aortic explants to Ang-1 (250ng/mL) resulted
in a robust angiogenic response. In contrast, the Ang-1-
induced vessel outgrowth was greatly diminished in db/db
mouse vessel explants compared with C57BL/6J mouse. In
the presence of OV, Ang-1-induced vessel outgrowth was
signiﬁcantly augmented compared to the db/db control
group (Figures 6(b) and 6(c)).
3.8. Inhibition of PTP Increases eNOS Expression and Cap-
illary Density in db/db Mouse Hearts. To examine whether
inhibition of PTP augments myocardial angiogenesis in
diabetic hearts, an orally bioavailable PTP inhibitor bis-
(maltolato)oxovanadium (IV) (BMOV) was given to the
experimental db/db mice. Treatment of db/db mice with
BMOV for 2 weeks resulted in a signiﬁcant decrease in
SHP-1 expression (Figure 7(a)). This was accompanied by
a signiﬁcant increase in eNOS expression in db/db mouse
hearts (Figure 7(b)). Immunohistochemical studies revealed
that myocardial capillary density was signiﬁcantly decreased
indb/dbmouseheartswhencomparedtoC57BL/6Jcontrols.
Myocardial capillary density was signiﬁcantly increased
in the BMOV-treated db/db mice (Figure 7(c)). Our ex
vivo angiogenesis studies also showed that Ang-1-induced
vessel outgrowth was signiﬁcantly improved in the BMOV-
treated db/db mice in comparison with db/db control group
(Figure 7(d)).
4. Discussion
The current study demonstrates that SHP-1 binds to the
Tie-2 to form a SHP-1/Tie-2 complex and that the Ang-
1, an agonist of Tie-2, causes SHP-1 dissociation from
Tie-2. This ﬁnding implicates a potential role of SHP-1
in Ang-1-induced Tie-2 phosphorylation. Intriguingly, high
glucose increases formation of the SHP-1/Tie-2 complex
and this is accompanied by Tie-2 dephosphorylation. Ang-
1 failed to cause SHP-1 dissociation from Tie-2 under HG
conditions. Suppression of SHP-1 expression signiﬁcantly
attenuated endothelial apoptosis and improved diabetes-
associated impairment of angiogenesis. These data strongly
suggest a critical role for SHP-1 and the SHP-1/Tie-2 associ-
ation in diabetes-associated impairment of angiogenesis.
The Src-homology-domain-2- (SH2-) containing tyro-
sine phosphatases (SHP-1 and SHP-2) have been shown to
interact with multiple growth factor receptors including Tie-
2[ 27, 28]. SHP-2 is primarily associated with enhanced cell
growth, whereas SHP-1 has been shown to play a negative
regulatory role in endothelial cell proliferation [18, 28–30].
SHP-1 suppresses VEGF and EGF-induced endothelial pro-
liferation, whereas knockdown of SHP-1 augments VEGF-
and FGF-2-induced angiogenic responses [20, 31]. SHP-
1 also showed to negatively modulate glucose homeostasis
via de-phosphorylation of insulin RTK signaling [32]. Our
study demonstrated that SHP-1 expression was signiﬁcantly
increased whereas SHP-2 expression remained unchanged
in diabetic db/db mouse hearts. Our present study also
demonstrated that SHP-1 works as a novel client protein for
Tie-2, and stimulation with Ang-1 led to SHP-1 dissociation
fromTie-2,implicatingapotentialinteractionbetweenSHP-
1 and Ang-1-induced Tie-2 phosphorylation. This notion
was further validated by our ﬁnding that exposure of
MHMEC to HG increased SHP-1/Tie-2 association but
decreased Tie-2 phosphorylation. This was consistent with
our previous studies that Ang-1-induced Tie-2 phosphoryla-
tion was damped under HG conditions [33]. Taken together,
the present study reveals a potential novel mechanism for the
disruption of Ang-1/Tie-2 signaling by SHP-1 in diabetes.
We speculate that protein tyrosine phosphatases, including
SHP-1, maintain Tie-2 inactivation by de-phosphorylation,
whereas stimulation with Ang-1 leads to dissociation of
SHP-1 from Tie-2 and results in Tie-2 phosphorylation and
its downstream signaling Akt and eNOS activation. Under
hyperglycemic conditions and in diabetes, stimulation with
Ang-1 fails to cause the dissociation of SHP-1 from Tie-2,
resulting in disruption of Ang-1/Tie-2 signaling (Figure 8).
Our data also demonstrated that knockdown of SHP-
1 by siRNA signiﬁcantly prevented HG-induced caspase-3Experimental Diabetes Research 9
activation and endothelial apoptosis. Our study further
demonstrates that inhibition of PTP augmented Ang-1-
induced cell survival under HG conditions and restored
angiogenic responses in diabetic vessel explants. Inhibition
of PTP has been shown to enhance angiogenic signaling
and promote VEGF-induced angiogenesis [34]. Inhibition
of PTP also promoted collateral blood vessel formation
and increased blood ﬂow in a rat model of hind-limb
ischemia [14, 15]. Inhibition of PTP has been shown to
attenuate endothelial dysfunction via upregulation of eNOS
in the mouse model of chronic heart failure [35]a n d
treatment with the nonselective PTP inhibitors such as
vanadate and BMOV-enhanced insulin receptor activation
and restored insulin signaling in diabetic rats [36–38].
T h ep r o t e c t i v ee ﬀect of PTP inhibitors on endothelial cell
dysfunction was mediated by the enhancement of Akt/eNOS
phosphorylation in diabetic rats [36]. Consistent with these
ﬁndings, our data showed that pretreatment of MHMEC
with a PTP inhibitor enhanced Ang-1-induced Akt/eNOS
phosphorylation. Our present study also demonstrated that
systemic treatment of diabetic db/db mouse with the PTP
inhibitor BMOV signiﬁcantly suppressed SHP-1 expression
and increased eNOS expression. This was accompanied by
increase in myocardial capillary density. Our study provides
new evidence that diabetes may impede angiogenesis by a
mechanism involving upregulation of PTP activity which
negatively regulates angiogenesis by inhibition of angiogenic
growth factor phosphorylation such as Ang-1/Tie-2 system.
4.1. Limitation of This Study. Other PTPs, including PTP1B,
SHP-2, PTP-ε, VE-PTP, CD148, may also play key roles
in the regulation of myocardial angiogenesis in diabetes.
Further elucidation of the intracellular mechanisms of PTP
with, such as, PTPB1 on diabetes-associated impairment
of angiogenic signaling and angiogenesis is needed. We
acknowledge that it is technically impossible to examine all
PTPs enzymes in a similar manner since speciﬁc inhibitors
are lacking for each individual isoform of the PTPs. We
also acknowledge the potential integrated eﬀects of SHP-1
and PKC beta signaling. Identiﬁcation of all the mechanisms
involved will require additional experiments to evaluate the
roles of PTPs and PKC signaling pathways in diabetes-
associated impairment of angiogenesis.
In summary, our present study demonstrates that hyper-
glycemia and diabetes impair angiogenesis by a mechanism
involving upregulation of SHP-1 and SHP-1/Tie-2 associa-
tion. Our study also shows that pharmacological inhibition
of PTP or genetic deletion of SHP-1 enhances Ang-1/Tie-
2 signaling and improves angiogenesis in diabetes. Our
data implicate that restoration of Ang-1/Tie-2 signaling by
PTP inhibitors should be considered as a new therapeutic
strategy for the treatment or prevention of diabetic impaired
angiogenesis.
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